Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Meridian, ID
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Meridian, ID
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Nampa, ID
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Nampa, ID
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Bloomington, IL
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Bloomington, IL
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Champaign, IL
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Champaign, IL
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Chicago, IL
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Elk Grove Village, IL
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Elk Grove Village, IL
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Elmhurst, IL
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Elmhurst, IL
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Evanston, IL
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Evanston, IL
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Flossmoor, IL
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Flossmoor, IL
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Research Site
mi
from
Herrin, IL
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Research Site
mi
from
Herrin, IL
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Lake Barrington, IL
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Lake Barrington, IL
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
mi
from
Lombard, IL
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
mi
from
Lombard, IL
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Melrose Park, IL
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Melrose Park, IL
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Niles, IL
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Niles, IL
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Research Site
mi
from
North Aurora, IL
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Research Site
mi
from
North Aurora, IL
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Palos Heights, IL
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Palos Heights, IL
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Peoria, IL
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Peoria, IL
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Research Site
mi
from
St. Charles, IL
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Research Site
mi
from
St. Charles, IL
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Anderson, IN
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Anderson, IN
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Bloomington, IN
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Bloomington, IN
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Elkhart, IN
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Elkhart, IN
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Evansville, IN
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Evansville, IN
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Fort Wayne, IN
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Indianapolis, IN
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Lafayette, IN
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Lafayette, IN
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Merrillville, IN
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Merrillville, IN
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Mishawaka, IN
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Mishawaka, IN
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Valparaiso, IN
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Valparaiso, IN
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Ames, IA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Ames, IA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Des Moines, IA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Des Moines, IA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Iowa City, IA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Iowa City, IA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Research Site
mi
from
West Burlington, IA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Research Site
mi
from
West Burlington, IA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Hays, KA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Hays, KA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Kansas City, KA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Kansas City, KA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Lenexa, KA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Lenexa, KA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Overland Park, KA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Overland Park, KA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Topeka, KA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Topeka, KA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Wichita, KA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Wichita, KA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Lexington, KY
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Lexington, KY
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Louisville, KY
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Paducah, KY
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Paducah, KY
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Alexandria, LA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Alexandria, LA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Baton Rouge, LA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Research Site
mi
from
Lacombe, LA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Research Site
mi
from
Lacombe, LA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Lafayette, LA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Lafayette, LA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
New Orleans, LA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
New Orleans, LA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Shreveport, LA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Shreveport, LA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Research Site
mi
from
Belfast, ME
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Research Site
mi
from
Belfast, ME
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Lewiston, ME
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Lewiston, ME
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Scarborough, ME
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Scarborough, ME
Click here to add this to my saved trials